Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchPemivibartPemivibart (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes       

Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19

Schmidt et al., New England Journal of Medicine, doi:10.1056/NEJMc2404555, NCT06039449
Nov 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Discussion of immunobridging data for the monoclonal antibody pemivibart for prevention of COVID-19 in immunocompromised individuals. Pemivibart received Emergency Use Authorization from the FDA based on safety and immunobridging data from the CANOPY trial showing neutralizing antibody titers consistent with the monoclonal antibody adintrevimab which had previously shown efficacy.
Schmidt et al., 14 Nov 2024, peer-reviewed, 3 authors, trial NCT06039449 (history). Contact: yli@invivyd.com.
This PaperPemivibartAll
Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19
Pete Schmidt, Yong Li, Myra Popejoy
New England Journal of Medicine, doi:10.1056/nejmc2404555
Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19 To the Editor: On March 22, 2024, the Food and Drug Administration issued Emergency Use Authorization (EUA) for the monoclonal antibody pemivibart as preexposure prophylaxis for Covid-19 in certain adults and adolescents with moderate-to-severe immunocompromise. The EUA was issued on the basis of safety and immunobridging data from the CANOPY trial (ClinicalTrials.gov number, NCT06039449), which included two cohorts: an open-label cohort of 306 persons with moderate-to-severe immunocompromise, who received an initial intravenous infusion of a single 4500-mg dose of pemivibart followed by a second infusion at the same dose approximately 90 days later, and a placebo-controlled cohort of persons without immunocompromise, who were randomly assigned to receive either pemivibart or placebo on the same schedule. Additional information is provided in the protocol and Supplementary Appendix, both of which are available with the full text of this letter at NEJM.org. The analysis of the primary end point was performed by means of an immunobridging method, which allowed for a comparison of the neutralizing antibody titers calculated for pemivibart with those calculated for the monoclonal antibody adintrevimab. Adintrevimab had shown efficacy against the B.1.617.2 (delta) variant but
{ 'indexed': { 'date-parts': [[2024, 11, 15]], 'date-time': '2024-11-15T05:33:49Z', 'timestamp': 1731648829388, 'version': '3.28.0'}, 'reference-count': 4, 'publisher': 'Massachusetts Medical Society', 'issue': '19', 'license': [ { 'start': { 'date-parts': [[2024, 11, 14]], 'date-time': '2024-11-14T00:00:00Z', 'timestamp': 1731542400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://www.nejmgroup.org/legal/terms-of-use.htm'}], 'funder': [{'name': 'Invivyd, Inc.'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': ['N Engl J Med'], 'published-print': {'date-parts': [[2024, 11, 14]]}, 'DOI': '10.1056/nejmc2404555', 'type': 'journal-article', 'created': { 'date-parts': [[2024, 11, 13]], 'date-time': '2024-11-13T22:00:27Z', 'timestamp': 1731535227000}, 'page': '1860-1862', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19'], 'prefix': '10.1056', 'volume': '391', 'author': [ { 'given': 'Pete', 'family': 'Schmidt', 'sequence': 'first', 'affiliation': [{'name': 'Invivyd, Waltham, MA'}]}, { 'given': 'Yong', 'family': 'Li', 'sequence': 'additional', 'affiliation': [{'name': 'Invivyd, Waltham, MA'}]}, { 'given': 'Myra', 'family': 'Popejoy', 'sequence': 'additional', 'affiliation': [{'name': 'Invivyd, Waltham, MA'}]}], 'member': '150', 'reference': [ {'key': 'e_1_3_3_2_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ofid/ofad314'}, {'key': 'e_1_3_3_3_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41467-023-40204-1'}, {'key': 'e_1_3_3_4_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41467-023-39292-w'}, { 'key': 'e_1_3_3_5_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/scitranslmed.adg2783'}], 'container-title': ['New England Journal of Medicine'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'http://www.nejm.org/doi/pdf/10.1056/NEJMc2404555', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 11, 14]], 'date-time': '2024-11-14T12:47:56Z', 'timestamp': 1731588476000}, 'score': 1, 'resource': {'primary': {'URL': 'http://www.nejm.org/doi/10.1056/NEJMc2404555'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 11, 14]]}, 'references-count': 4, 'journal-issue': {'issue': '19', 'published-print': {'date-parts': [[2024, 11, 14]]}}, 'alternative-id': ['10.1056/NEJMc2404555'], 'URL': 'http://dx.doi.org/10.1056/nejmc2404555', 'relation': {}, 'ISSN': ['0028-4793', '1533-4406'], 'issn-type': [{'type': 'print', 'value': '0028-4793'}, {'type': 'electronic', 'value': '1533-4406'}], 'subject': [], 'published': {'date-parts': [[2024, 11, 14]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit